Literature DB >> 17184390

Retrospective cost-effectiveness analyses for polio vaccination in the United States.

Kimberly M Thompson1, Radboud J Duintjer Tebbens.   

Abstract

The history of polio vaccination in the United States spans 50 years and includes different phases of the disease, multiple vaccines, and a sustained significant commitment of resources. We estimated cost-effectiveness ratios and assessed the net benefits of polio vaccination applicable at various points in time from the societal perspective and we discounted these back to appropriate points in time. We reconstructed vaccine price data from available sources and used these to retrospectively estimate the total costs of the U.S. historical polio vaccination strategies (all costs reported in year 2002 dollars). We estimate that the United States invested approximately US dollars 35 billion (1955 net present value, discount rate of 3%) in polio vaccines between 1955 and 2005 and will invest approximately US dollars 1.4 billion (1955 net present value, or US dollars 6.3 billion in 2006 net present value) between 2006 and 2015 assuming a policy of continued use of inactivated poliovirus vaccine (IPV) for routine vaccination. The historical and future investments translate into over 1.7 billion vaccinations that prevent approximately 1.1 million cases of paralytic polio and over 160,000 deaths (1955 net present values of approximately 480,000 cases and 73,000 deaths). Due to treatment cost savings, the investment implies net benefits of approximately US dollars 180 billion (1955 net present value), even without incorporating the intangible costs of suffering and death and of averted fear. Retrospectively, the U.S. investment in polio vaccination represents a highly valuable, cost-saving public health program. Observed changes in the cost-effectiveness ratio estimates over time suggest the need for living economic models for interventions that appropriately change with time. This article also demonstrates that estimates of cost-effectiveness ratios at any single time point may fail to adequately consider the context of the investment made to date and the importance of population and other dynamics, and shows the importance of dynamic modeling.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17184390     DOI: 10.1111/j.1539-6924.2006.00831.x

Source DB:  PubMed          Journal:  Risk Anal        ISSN: 0272-4332            Impact factor:   4.000


  28 in total

1.  Trends in the risk of U.S. polio outbreaks and poliovirus vaccine availability for response.

Authors:  Kimberly M Thompson; Gregory S Wallace; Radboud J Duintjer Tebbens; Philip J Smith; Albert E Barskey; Mark A Pallansch; Kathleen M Gallagher; James P Alexander; Gregory L Armstrong; Stephen L Cochi; Steven G F Wassilak
Journal:  Public Health Rep       Date:  2012 Jan-Feb       Impact factor: 2.792

2.  Eradicating polio: the dollars and sense.

Authors:  Kimberly M Thompson
Journal:  MedGenMed       Date:  2007-10-15

3.  The risks, costs, and benefits of possible future global policies for managing polioviruses.

Authors:  Kimberly M Thompson; Radboud J Duintjer Tebbens; Mark A Pallansch; Olen M Kew; Roland W Sutter; R Bruce Aylward; Margaret Watkins; Howard E Gary; James Alexander; Hamid Jafari; Stephen L Cochi
Journal:  Am J Public Health       Date:  2008-05-29       Impact factor: 9.308

4.  Modeling population immunity to support efforts to end the transmission of live polioviruses.

Authors:  Kimberly M Thompson; Mark A Pallansch; Radboud J Duintjer Tebbens; Steve G Wassilak; Stephen L Cochi
Journal:  Risk Anal       Date:  2012-09-17       Impact factor: 4.000

5.  Preeradication vaccine policy options for poliovirus infection and disease control.

Authors:  Kimberly M Thompson; Mark A Pallansch; Radboud J Duintjer Tebbens; Steve G Wassilak; Jong-Hoon Kim; Stephen L Cochi
Journal:  Risk Anal       Date:  2013-03-05       Impact factor: 4.000

6.  Modeling poliovirus risks and the legacy of polio eradication.

Authors:  Kimberly M Thompson
Journal:  Risk Anal       Date:  2013-03-28       Impact factor: 4.000

7.  Enhancing the work of the Department of Health and Human Services national vaccine program in global immunization: recommendations of the National Vaccine Advisory Committee: approved by the National Vaccine Advisory Committee on September 12, 2013.

Authors: 
Journal:  Public Health Rep       Date:  2014       Impact factor: 2.792

8.  Long-term socio-economic consequences and health care costs of poliomyelitis: a historical cohort study involving 3606 polio patients.

Authors:  Nete Munk Nielsen; Lise Kay; Benedikte Wanscher; Rikke Ibsen; Jakob Kjellberg; Poul Jennum
Journal:  J Neurol       Date:  2016-04-15       Impact factor: 4.849

9.  Evaluation of IRES-mediated, cell-type-specific cytotoxicity of poliovirus using a colorimetric cell proliferation assay.

Authors:  Xiaoyi Yang; Eying Chen; Hengguang Jiang; Karen Muszynski; Raymond D Harris; Steven L Giardina; Matthias Gromeier; Gautam Mitra; Gopalan Soman
Journal:  J Virol Methods       Date:  2008-11-08       Impact factor: 2.014

10.  The Economic Value of Vaccination: Why Prevention is Wealth.

Authors: 
Journal:  J Mark Access Health Policy       Date:  2015-08-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.